[{"data":1,"prerenderedAt":156},["ShallowReactive",2],{"drug-treprostinil":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":58,"warnings":59,"renal":67,"monitoring":68,"interactions":69,"review":70,"examples":73,"atc":74,"iran":76,"usApproval":96,"links":102,"populations":121},"treprostinil",1,{"fa":7,"en":8},"ترپروستینیل","Treprostinil","blood",{"fa":11,"en":12},"آنالوگ پروستاسیکلین","Prostacyclin analogue",[14],{"name":15,"market":16},"Remodulin","US",[18,19,7],"remodulin","رمودولین",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"vial-1","injection","sc","1 mg\u002FmL, 20 mL vial (also 0.1–20 mg\u002FmL)",{"amount":5,"unit":27,"perVolumeMl":5},"mg",[16],[30],{"source":31,"section":32},"fda-remodulin","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":27,"dose":45,"refs":49},"pah","pulmonary-arterial-hypertension",{"fa":38,"en":39},"PAH (WHO گروه ۱، NYHA II–IV) — انفوزیون مداوم زیرجلدی (ترجیحی) یا وریدی مرکزی؛ شروع ۱٫۲۵ نانوگرم\u002Fkg\u002Fدقیقه","PAH (WHO group 1, NYHA II–IV) — continuous SC (preferred) or central IV infusion; start 1.25 ng\u002Fkg\u002Fmin",{"minAge":41},{"value":42,"unit":43},18,"year","notCalculated",{"reason":46},{"fa":47,"en":48},"دوز بر حسب نانوگرم\u002Fkg\u002Fدقیقه با پمپ تیتر می‌شود: افزایش ۱٫۲۵ در هفته طی ۴ هفته اول، سپس ۲٫۵ در هفته. تحمل نشد: ۰٫۶۲۵. نارسایی خفیف تا متوسط کبد: شروع ۰٫۶۲۵. قطع ناگهانی ممنوع. انتقال از اپوپروستنول در بیمارستان.","Dosed in ng\u002Fkg\u002Fmin by pump: increase 1.25 per week for the first 4 weeks, then 2.5 per week. Not tolerated: 0.625. Mild–moderate hepatic impairment: start 0.625. Avoid abrupt cessation. Transition from epoprostenol in hospital.",[50,52,54,56],{"source":31,"section":51},"2.2",{"source":31,"section":53},"2.4",{"source":31,"section":55},"2.5",{"source":31,"section":57},"2.7",[],[60],{"text":61,"refs":64},{"fa":62,"en":63},"عفونت خونی مرتبط با کاتتر وریدی؛ بدتر شدن PAH با قطع ناگهانی؛ افت فشار؛ خونریزی.","Catheter-related bloodstream infection with IV use; worsening PAH on abrupt withdrawal; hypotension; bleeding.",[65],{"source":31,"section":66},"5",[],[],[],{"status":71,"reviewer":72,"date":72},"unverified",null,[],[75],"B01AC21",{"status":77,"forms":78,"refs":91},"registered",[79,83,87],{"code":80,"en":81,"fa":82},"53085","TREPROSTINIL (AS SODIUM) INJECTION PARENTERAL 5 mg\u002F1mL 10 mL","فرآورده تزریقی ترپروستینیل (معادل سدیم) ۵ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",{"code":84,"en":85,"fa":86},"53084","TREPROSTINIL (AS SODIUM) INJECTION PARENTERAL 2.5 mg\u002F1mL 10 mL","فرآورده تزریقی ترپروستینیل (معادل سدیم) ۲٫۵ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",{"code":88,"en":89,"fa":90},"53083","TREPROSTINIL (AS SODIUM) INJECTION PARENTERAL 1 mg\u002F1mL 10 mL","فرآورده تزریقی ترپروستینیل (معادل سدیم) ۱ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",[92],{"source":93,"section":94,"url":95},"darooyab-generic","G-3195\u002FTreprostinil","https:\u002F\u002Fwww.darooyab.ir\u002FG-3195\u002FTreprostinil",{"kind":97,"refs":98,"id":101},"NDA",[99],{"source":31,"section":100},"SPL approval \u002F marketing category","NDA021272",[103,106,110,113,116,119],{"kind":104,"url":105,"label":101},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021272",{"kind":107,"url":108,"label":109},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6c80bb38-e8db-4138-9f0d-dbbf9c673185","FDA Remodulin",{"kind":111,"url":112,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622040.html",{"kind":111,"url":114,"label":115},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622038.html","Treprostinil Injection",{"kind":117,"url":118,"label":75},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC21",{"kind":120,"url":95,"label":8},"darooyab",{"pregnancy":122,"lactation":131,"pediatric":139,"geriatric":148},{"level":123,"text":124,"quote":127,"refs":128},"caution",{"fa":125,"en":126},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.",[129],{"source":31,"section":130},"8.1",{"level":123,"text":132,"quote":135,"refs":136},{"fa":133,"en":134},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.",[137],{"source":31,"section":138},"8.2",{"level":140,"text":141,"quote":144,"refs":145},"not-established",{"fa":142,"en":143},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[146],{"source":31,"section":147},"8.4",{"level":123,"text":149,"quote":152,"refs":153},{"fa":150,"en":151},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[154],{"source":31,"section":155},"8.5",1792444427172]